Achim Moesta

Company: Trishula Therapeutics, Inc.

Job title: Executive Director, Vice President & Head of Immunology & Translational Sciences

Seminars:

Panel Discussion – Barriers to Development of CD73/CD39 Mono and Combo Therapies and Potential Solutions 11:00 am

Compare and contrast single vs dual inhibition of adenosine enzymes Explore current challenges with identifying and validating predictive biomarkers of response Suggest methods and technologies worth pursuing to better select patients for trialsRead more

day: Day Two

Improving Outcomes for People With Cancer By Developing TTX-030, A First- In-Class, Anti-CD39 Antibody 10:30 am

Explore translational practices and how they can be improved for greater confidence upon reaching the clinic Using novel approaches to inform clinical decision makingRead more

day: Day Two

Panel Discussion – Selecting Combination Partners Rationally 11:30 am

What types of features should we look for in a potential combination partner for CD73/CD39 inhibitors? What can we identify as being a good partner for A2AR and A2B? Discuss a methodology that can be used as a process for assessing potential combination partners that improves patient responses and safety profiles Postulate what partners have…Read more

day: Day One